J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
|
|
- Annabelle Willis
- 5 years ago
- Views:
Transcription
1 VOLUME 22 NUMBER 22 NOVEMBER JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia: Phase II Trial (E8296) of the Eastern Cooperative Oncology Group Mary Armanios, Ronghui Xu, Arlene A. Forastiere, Daniel G. Haller, John W. Kugler, and Al B. Benson III From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL Submitted June 4, 2004; accepted August 30, This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA16116, CA15488, CA13650, CA17145, and from the National Cancer Institute, the National Institutes of Health, and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Study presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Mary Armanios, MD, Johns Hopkins University, 1650 Orleans St, CRB 186, Baltimore, MD 21205; marmani1@jhmi.edu by American Society of Clinical Oncology X/04/ /$20.00 DOI: /JCO A B S T R A C T Purpose To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia. Patients and Methods We conducted a multicenter phase II trial. Patients had pathologically staged T2 nodepositive to T3-4, any node status adenocarcinoma of the distal esophagus, GE junction, or gastric cardia with negative margins (R0). Treatment consisted of four cycles of paclitaxel 175 mg/m 2 intravenously (IV) over 3 hours followed by cisplatin 75 mg/m 2 IV every 21 days. A positive outcome was considered to be an improvement in 2-year survival rate by 20% compared to historic controls. Results Fifty-nine patients were recruited from 20 centers. Of 55 eligible patients, 49 (89%) had lymph node involvement. Forty-six patients (84%) completed all four cycles. Of the total 59 patients, 31 (56%) developed grade 3 or 4 toxicity with leukopenia/neutropenia, nausea/ vomiting, and metabolic toxicities were most common. The median follow-up for surviving patients was 4 years. At 2 years, 33 patients were alive and 22 were dead, with a survival rate of 60% (95% CI, 46% to 73%; one-sided P.0008 compared with the historic controls). Conclusion Our data suggest that adjuvant paclitaxel and cisplatin may improve survival in R0 resected patients with locally advanced adenocarcinoma of the distal esophagus, GE junction, and cardia. These results warrant further testing in randomized trials. J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION Adenocarcinoma of the esophagus accounts for 60% of all esophageal cancers in the United States. For complex reasons that remain unclear, its incidence continues to rise. Surgical resection remains a standard of care, and two-thirds of patients with locoregional disease can undergo potentially curative resection. 1 However, despite aggressive surgical treatment, only one-third of patients undergoing curative resection are alive beyond 2 years, with the majority developing distant metastases most commonly in the lungs, liver, and bone. 2,3 Adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia is generally regarded as a unique clinical entity. This grouping is based on epidemiologic data showing a predominance of disease in males, an association with Barrett s esophagus in the majority of 4495
2 Armanios et al patients, and a similar pattern of spread to lower esophageal nodes. 4 Clinically, adenocarcinoma of the cardia shares a common distant pattern of recurrence with esophageal and GE junction cancers. This distinguishes it from other gastric cancers in which local failure patterns predominate. Although some have advocated the use of a separate staging system for these esophagocardia cancers, they continue to be staged based on traditional anatomic boundaries, although treatment planning may differ. Postoperative chemotherapy has not been studied in the randomized setting as a sole adjunctive modality to surgery in adenocarcinoma of the esophagus. The INT0116 trial evaluated chemoradiotherapy in patients with completely resected adenocarcinoma of the stomach and found a 7-month improvement in median survival in the treatment arm compared with the surgery-alone arm. 5 Twenty percent of the treated patients had disease in the cardia or GE junction, but the study was not statistically powered to measure a survival difference in this subset. In squamous cell carcinoma, the Japanese Clinical Oncology Group randomly assigned 242 patients with R0 resection to postoperative fluorouracil and cisplatin compared to observation and found no overall survival benefit at 5 years. 6 A subset analysis showed a significant survival improvement with adjuvant chemotherapy in patients with pathologically affected lymph nodes compared with patients who had no affected nodes. However, in squamous cell carcinoma, as in the Japanese cohort, the dominant pattern of first recurrence is local and patients often have comorbidities affecting their tolerance to adjuvant treatment. Although the survival, stage-for-stage, appears to be comparable in both histologies, 3,7,8 the pattern of failure is well established to be different. Cisplatin-based chemotherapy has long been the backbone of treatment in esophageal cancers 9 and paclitaxel is active as a single agent. 10,11 The combination of paclitaxel and cisplatin was tested in patients with advanced esophageal carcinomas with an objective response of 49%. 12,13 We thus designed a phase II, multicenter study to evaluate the impact on survival of postoperative chemotherapy in patients with curatively resected esophageal adenocarcinoma. Radiation therapy was not included because of the predominantly distant pattern of recurrence. PATIENTS AND METHODS Eligibility Criteria Eligibility criteria included: age 18 years; ability to give informed consent; histologic proof of adenocarcinoma of the esophagus, GE junction, or cardia status post total resection (transhiatal or transthoracic), and pathologic stage from T2 nodepositive M0 to T3-4 any node status, M0 disease, with negative proximal and distal margins (R0 resection); and Eastern Cooperative Oncology Group performance status 0 or 1. Patients were enrolled 4 to 12 weeks from the date of surgery and had to be without clinical evidence of locoregional or distant recurrence as assessed by computed tomography (CT) scan of the chest, abdomen and pelvis and with stable or increasing weight at the time of protocol entry. Treatment was started within 3 days of enrollment. Adequate organ function was required within 2 weeks of registration and was defined as: absolute neutrophil count (ANC) 1,500/mm 3, platelets 120,000/ mm 3, serum creatinine or creatinine clearance (CrCl) within normal institutional limits, AST and bilirubin the institutional upper limit of normal. Initial dose modification was not needed for bilirubin between1.5 to 2.0 mg/dl. No prior chemotherapy or concurrent radiation therapy was allowed. Patients were required to be without clinically significant hearing loss or symptomatic peripheral neuropathy as judged by initial history and physical examination. Institutional review and approval were required. Treatment The regimen consisted of paclitaxel 175 mg/m 2 intravenously (IV) as a 3-hour infusion on day 1, followed by cisplatin 75 mg/m 2 IV on day 1 repeated every 3 weeks for a total of four cycles. Appropriate premedications, antiemetics, and hydration were recommended. Dose Modification All toxicities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria. To receive treatment, patients had to have an ANC 1,500/mm 3 and platelets 100,000/mm 3 on day 1 of therapy. Dose modification based on nadir toxicity of previous cycle was allowed with grade 4 neutropenia lasting 5 days, or febrile/neutropenia requiring hospitalization, or grade 4 thrombocytopenia requiring a reduction of both doses by 20%. For renal dysfunction, no modification of the paclitaxel dose was made. Creatinine clearance was required when the creatinine was above normal for institutions. For a CrCl 50 ml/min, no dose modification was made; 40 to 49, a 50% dose reduction was made; and CrCl 40, no cisplatin was given. Patients who developed grade 3 or 4 sensory or motor neuropathy defined as mild to moderate parastehesias, hearing loss, or objective weakness interfering with function had treatment terminated. Treatment was terminated early if objective disease recurrence was seen, if unacceptable toxicity developed, or if the patient wished to stop. Patient Evaluation The designations of distal esophagus, GE junction, and cardia primary site were determined by the local pathologist based on the main bulk of the tumor as per the American Joint Committee on Cancer Staging Manual criteria. 14 Pathologic staging systems for both esophageal and gastric cancer were used when the epicenter of disease bridged the GE junction. Cardia cancers were defined as being within 2 cm from the GE junction. Pathology reports were centrally reviewed by the study chair to confirm eligibility and disease site designation. Patients were followed every 3 months starting 3 weeks after the final cycle of treatment for 2 years, then every 6 months from 2 to 5 years, and yearly thereafter. CT scans were obtained every 6 months up to 4 years. Study Design The primary end point was 2-year survival. Secondary end points were disease-free survival time and feasibility (compliance 4496 JOURNAL OF CLINICAL ONCOLOGY
3 Adjuvant Therapy for Esophageal Adenocarcinoma and toxicity) of administering four courses of paclitaxel and cisplatin after esophagogastrectomy. Statistical Methods The study was designed to have 90% power to detect a 20% improvement in the 2-year survival rate from 38% to 58% (onesided P-value of.05). The preset 2-year survival was based on data from 135 patients in the surgery control arm of the United States intergroup trial INT0113 who underwent R0 resection. 7 The accrual goal was 55 patients, assuming that 50 would be eligible. No early stopping was planned in the design. Overall survival was defined as the time from study entry to death. Disease-free survival was the time from study entry to disease recurrence (defined as the date of biopsy-proven recurrence or clear evidence of progression by CT) or death of any cause. Overall survival and disease-free survival curves were generated by the Kaplan-Meier method. RESULTS Between June 1998 and March 2000, 59 patients were enrolled in 20 centers. Of these, 55 were eligible; four were ineligible (two with positive margins, one distal gastric cancer, and one metastatic disease). This analysis was performed in April Patient characteristics are shown in Table 1. The majority of patients were male with T3N1, GE Table 1. Patient Characteristics No. of Patients % Total patients 59 Eligible Age, years Median 62 Range Sex Female 3 5 Male ECOG performance status Primary sites Distal esophagus 9 16 T2N1 4 T3N1 5 GE junction T2N1 1 T3N0 4 T3N1 27 T3N2 1 T4N1 1 Cardia T2N1 3 T3N0 2 T3N1 4 T3N2 3 Abbreviations: ECOG, Eastern Cooperative Oncology Group; GE, gastro-esophageal. junction cancers. Forty-nine (89%) of 55 patients had positive lymph nodes. Two patients with primary disease in the cardia had pathologically affected celiac lymph nodes. Both of these patients died from metastatic disease within 3 years of the surgery date. Forty-six patients (84%) completed all four cycles of therapy, and the mean number of cycles administered was 3.7. Table 2 provides the grade 3/4 toxicities. Of the total 59 patients (including four ineligible patients), 32 (54%) developed grade 3 or 4 toxicity with leukopenia or neutropenia (16 of 59 patients), and nausea/vomiting (seven of 59 patients), with metabolic (five of 59 patients) and sensory/ motor neuropathy (five of 59 patients) as the most common toxicities. One patient died suddenly on day 18 of cycle 1 of an unclear cause. At 2 years, 33 of 55 eligible patients were alive with a survival rate of 60% (95% CI, 46% to 73%). This rejects the projected 2-year survival rate of 38% with surgery alone under the null hypothesis with a one-sided P-value of At the time of analysis, the median follow-up is 4 years (range, 2.9 to 4.9 years) for the 17 surviving patients. Figure 1 shows the Kaplan-Meier curves of the overall survival and of the diseasefree survival for all eligible patients. The median survival is 2.6 years with a median disease-free survival of 1.6 years. One-year and 3-year survivals are 80% and 42%, respectively. Sites of first failure in 38 patients are shown in Table 3. As expected, distant metastasis was predominant. Table 2. Adverse Events (N 59) No. of Patients Adverse Event Grade 3 Grade 4 Leukopenia/neutropenia 9/0 4/3 Neurologic 5 0 Metabolic 5 1 Nausea 5 Arthralgia/myalgia 2/1 Anorexia 2 Hypotension 2 1 Anemia 1 Infection 1 Febrile neutropenia 1 Vomiting 1 1 Diarrhea 1 1 Phlebitis 1 Weight loss 1 Fatigue 1 Dehydration 1 Pain 1 Worst degree NOTE. Adverse events graded according to the National Cancer Institute Common Toxicity Criteria. One patient died on day 18 of cycle 1 of unclear cause
4 Armanios et al Table 3. Site of First Recurrence (n 55) Site No. of Patients % Distant Locoregional (anastomosis, duodenal) 2 5 Both local and distant 3 8 Unknown 4 11 Total 38 Fig 1. Kaplan-Meier curves of (A) overall and (B) disease-free survival of eligible patients. The dashes represent pointwise 95% CIs. Survival at 1, 2, and 3 years was 80%, 60%, and 44%, respectively. At 2 years, this was statistically significant with a P-value of DISCUSSION We conducted a multi-institutional phase II study to assess the effect of adjuvant cisplatin and paclitaxel on the survival of patients with R0 resected, locally advanced adenocarcinoma of the distal esophagus, GE junction, and cardia. We found a statistically significant benefit compared with historic controls who underwent a similar R0 resection as their only therapy in INT0113. To our knowledge, this is the first multicenter trial of its kind and the first to show benefit compared with historic controls. In general, the therapy was tolerable with manageable toxicities and the majority of patients were able to complete it fully. A few important differences are worth noting. In INT0113, the surgery arm patients were enrolled preoperatively and their survival was measured from the time of study entry. The INT0113 intention-to-treat survival analysis included 6% of patients who died from surgery-related complications. In contrast, E8296 patients were enrolled 4 to 12 weeks after surgery and had to fit eligibility criteria of adequate performance and nutritional status. These latter criteria may, therefore, knowingly introduce a selection bias and are an attempt to offer systemic therapy to high-risk patients who recover well after surgery. A larger European trial of perioperative chemotherapy also included a surgery control arm that may be considered comparable to our group of patients. The Medical Research Council trial randomly assigned 802 patients with squamous cell and adenocarcinoma of the esophagus to immediate surgery compared with two cycles of cisplatin and fluorouracil followed by surgery. A statistically significant improvement in survival was found in the treatment arm. This benefit also held in the subset analysis of 533 patients with adenocarcinoma where the 2-year survival in the surgery only arm (n 268) was 30%. These statistics are from patients who were also enrolled preoperatively and were eligible regardless of postoperative disease status (ie, residual micro- or macroscopic residual disease). Taken together, such differences make accurate historic control comparisons difficult and can only be resolved in a headto-head randomized trial. For the moment, our results suggest a possible survival improvement compared with surgery alone and further studies of postoperative chemotherapy seem feasible and warranted in this population. Finally, since the launching of this trial, there have been changes in practice which may contribute to better defining the role of adjuvant therapy today. Several trials have demonstrated the superiority of positron emission tomography over CT in detecting subclinical distant metastases JOURNAL OF CLINICAL ONCOLOGY
5 Adjuvant Therapy for Esophageal Adenocarcinoma Primary surgery in this setting is generally noncurative with most patients relapsing within 1 year With appropriate staging of patients who have localized disease at presentation, it may prove easier to measure benefits from adjuvant treatment. In addition, there has been a trend to treat patients with locoregional disease with upfront chemoradiotherapy followed by surgical resection. Although controversy remains as to the impact of this approach on survival, 2,18-21 it continues to be used because of its tolerability as well as based on improvements in locoregional control. 22 Furthermore, in patients who are downstaged to pathologic complete responses, 25% to 30% of all comers, or those with minimal residual disease (eg, T1), long-term survival can be achieved. 23,24 For patients with more residual disease, the outcome remains poor, with, as in our patients, distant failure predominating. This pattern of failure underscores the need for better systemic therapy to address and change the natural history of this disease. We have shown in this phase II multicenter trial a statistically significant improvement in survival in patients with R0 resected, predominantly node-positive adenocarcinoma of the distal esophagus, GE junction, and cardia compared with historic controls. Approaches using adjuvant systemic therapy warrant further study in randomized trials. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES 1. Schrump DS, Forastiere AA, Minsky BD: Cancer of the Esophagus, in DeVita V (ed): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2001, pp Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: , Mariette C, Balon JM, Piessen G, et al: Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97: , MacDonald WC, MacDonald JB: Adenocarcinoma of the esophagus and/or gastric cardia. Cancer 60: , Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: , Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study JCOG9204. J Clin Oncol 21: , Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: , Salazar JD, Doty JR, Lin JW, et al: Does cell type influence post-esophagectomy survival in patients with esophageal cancer? Dis Esophagus 11: , Leichman L, Steiger Z, Seydel HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach. J Clin Oncol 2:75-79, Kelsen D, Ajani J, Ilson D, et al: A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: Preliminary report. Semin Oncol 21:44-48, Ajani JA, Ilson DH, Daugherty K, et al: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86: , Ilson DH, Forastiere A, Arquette M, et al: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6: , Kelsen D, Ginsberg R, Bains M, et al: A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: A preliminary report. Semin Oncol 24: S19-77-S19-81, American Joint Committee on Cancer.Esophagus and Gastric (5th ed). Philadelphia, J.B. Lippincott, Luketich JD, Schauer PR, Meltzer CC, et al: Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64: , Kole AC, Plukker JT, Nieweg OE, et al: Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78: , Rasanen JV, Sihvo EI, Knuuti MJ, et al: Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10: , Gibson MK, Forastiere AA: Combinedmodality therapy for esophageal cancer: Are we making progress? Cancer J 9: , Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: , Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: , Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359: , Kleinberg L, Knisely JP, Heitmiller R, et al: Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 56: , Heath EI, Burtness BA, Heitmiller RF, et al: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18: , Ajani JA, Faust J, Yao J, et al: Irinotecan/ cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Huntingt) 17:20-22,
Although esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationCHEMOTHERAPY FOLLOWED BY SURGERY VS. SURGERY ALONE FOR LOCALIZED ESOPHAGEAL CANCER
CHEMOTHERAPY FOLLOWED BY VS. ALONE FOR LOCALIZED ESOPHAGEAL CANCER CHEMOTHERAPY FOLLOWED BY COMPARED WITH ALONE FOR LOCALIZED ESOPHAGEAL CANCER DAVID P. KELSEN, M.D., ROBERT GINSBERG, M.D., THOMAS F. PAJAK,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationThe prognosis for patients with esophageal cancer is poor.
ORIGINAL ARTICLE A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer Henry Wang, MD, Janice Ryu, MD, David Gandara, MD, Richard J. Bold, MD, Shiro Urayama,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationEsophageal cancer located at the cervical and upper thoracic
ORIGINAL ARTICLE Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single- Institution Experience Shulian Wang, MD,* Zhongxing Liao, MD, Yuan Chen, MD, Joe
More informationAdenocarcinoma of gastro-esophageal junction - Case report
Case Report denocarcinoma of gastro-esophageal junction - Case report nupsingh Dhakre 1*, Ibethoi Yengkhom 2, Harshin Nagori 1, nup Kurele 1, Shreedevi. Patel 3 1 2 nd year Resident, 2 3rd year Resident,
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationSurgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?
Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours? Question #2: How are cardia tumours managed? Michael F. Humer December 3, 2005 Vancouver, BC Case
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationAdenocarcinoma of the distal esophagus and gastroesophageal
Original Article A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationPerioperative versus adjuvant management of gastric cancer, update 2013
Perioperative versus adjuvant management of gastric cancer, update 2013 Cornelis J.H. van de Velde, MD, PhD,FRCPS and FACS,Hon. Professor of Surgery President ECCO - the European Cancer Organization Past-President
More information17. Oesophagus. Upper gastrointestinal cancer
110 17. Upper gastrointestinal cancer Oesophagus Radical treatment For patients with localised disease, the standard curative approach to treatment is either surgery + perioperative chemotherapy, surgery
More informationDoes the Timing of Esophagectomy After Chemoradiation Affect Outcome?
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationJournal Annals of surgical oncology, 19(1): The final publication is available
A randomized trial comparing postop chemotherapy with cisplatin and 5-f Titleversus preoperative chemotherapy fo advanced squamous cell carcinoma of esophagus (JCOG9907) Ando, N; Kato, H; Igaki, H; Author(s)
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationLymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma
The American Journal of Surgery (2013) 205, 711-717 Clinical Surgery Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma Magali Cabau, M.D. a, Guillaume
More informationORIGINAL ARTICLE. aggressive disease with a poor prognosis. Its incidence in the United States has been increasing;
Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is It Worthwhile? ORIGINAL ARTICLE Wael Z. Tamim, MD; Robert S. Davidson, MD; Robert M. Quinlan, MD; Michael A. O Shea, MB, BCh; Richard K. Orr, MD;
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationUtility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer
ORIGINAL ARTICLES: GENERAL THORACIC Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene M. Correa, PhD,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationClinical Aspects of Multimodality Therapy for Resectable Locoregional Esophageal Cancer
Review Clinical Aspects of Multimodality Therapy for Resectable Locoregiol Esophageal Cancer Masayuki Shinoda, MD, Shunzo Hatooka, MD, Shoichi Mori, MD, and Tetsuya Mitsudomi, MD Radical resection has
More informationAccuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis
Review Article Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis Ravi Shridhar 1, Jamie Huston 2, Kenneth L. Meredith 2 1 Department of Radiation
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationAggressive Multimodality Therapy for Stage III Esophageal Cancer: A Phase I/II Study
Aggressive Multimodality Therapy for Stage III Esophageal Cancer: A Phase I/II Study E. Pendleton Alexander, MD, Timothy Lipman, MD, John Harmon, MD, and Robert Wadleigh, MD Divisions of Cardiothoracic
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationBarrett s esophagus is a recognized predisposing condition
Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett s Esophagus and Symptomatic Gastroesophageal Reflux Banke Agarwal, MD, Stephen
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationEASTERN COOPERATIVE ONCOLOGY GROUP
EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR
More informationThe CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial
Editorial The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial Ian Wong, Simon Law Division of Esophageal and Upper Gastrointestinal Surgery, Department of Surgery,
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationSETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.
OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower
More informationEsophageal carcinomas in 2012 affected 17,460 Americans,
Original Article A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas Hoosier Oncology Group G05-92 Carlos R. Becerra, MD,*
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationPerioperative management of esophageal cancer
Perioperative management of esophageal cancer Lucas Goense Perioperative management of esophageal cancer Lucas Goense Perioperative management of esophageal cancer PhD thesis, Utrecht University, The
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationdoi: /theoncologist
Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Mary Koshy, Natia Esiashvilli, Jerome C. Landry, Charles R. Thomas, Jr. and Richard H. Matthews The Oncologist
More informationEsophagus and gastroesophageal junction (GEJ) cancer is a
ORIGINAL ARTICLE A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal
More informationEsophageal cancer is predicted to afflict 16,980 individuals
ORIGINAL ARTICLE Trimodality Therapy for Stage II III Carcinoma of the Esophagus: A Dose-Ranging Study of Concurrent Capecitabine,, and Thoracic Radiotherapy Matthew D. Wood, MD, PhD,* Bassem I. Zaki,
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationImpact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
Gastric Cancer (219) 22:369 376 https://doi.org/1.7/s112-18-875-1 ORIGINAL ARTICLE Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial
More informationA Retrospective Study of Survival and Patterns of Failure in Gastric Cancer after Adjuvant Chemoradiation
Med. J. Cairo Univ., Vol. 82, No. 2, December: 131-138, 2014 www.medicaljournalofcairouniversity.net A Retrospective Study of Survival and Patterns of Failure in Gastric Cancer after Adjuvant Chemoradiation
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationPrimary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients?
DOI 10.1186/s40001-017-0265-x European Journal of Medical Research RESEARCH Open Access Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationPrinted by Hadi Ranjkeshzadeh on 11/12/2010 4:40:23 PM. For personal use only. Not approved for distribution. Copyright 2010 National Comprehensive
Discussion Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform consensus. Category 2A: The recommendation
More informationUpdated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationMichael A. Choti, MD, FACS Department of Surgery Johns Hopkins Medicine, Baltimore, MD
Michael A. Choti, MD, FACS Department of Surgery Johns Hopkins Medicine, Baltimore, MD Surgical Therapy of Gastric Cancer CLINICAL QUESTIONS 1. How much of the stomach should be removed? 2. How many lymph
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationAccepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen,
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationCapizzello A, Tsekeris PG, Pakos EE, Papathanasopoulou V, Pitouli EJ. Correspondence to: Emilios E. Pakos,
Original Article Adjuvant chemo-radiotherapy in patients with gastric cancer Capizzello A, Tsekeris PG, Pakos EE, Papathanasopoulou V, Pitouli EJ Department of Radiation Therapy, University Hospital of
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationAm J Cancer Res 2016;6(10): /ISSN: /ajcr
Am J Cancer Res 2016;6(10):2345-2350 www.ajcr.us /ISSN:2156-6976/ajcr0037407 Original Article Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced
More informationNCCP Chemotherapy Regimen
Carboplatin (AUC 2) Weekly and Paclitaxel (50mg/m 2 ) Weekly with Radiotherapy (RT) -5 weeks INDICATIONS FOR USE: Regimen Code 00422a *Reimbursement Indicator INDICATION ICD10 Preoperative chemoradiation
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationClinical Evaluation of Low-dose Cisplatin and 5-Fluorouracil as Adjuvant Chemoradiotherapy for Advanced Squamous Cell Carcinoma of the Esophagus
Hiroshima J. Med. Sci. Vol. 54, No. 3, 67-71, September, 25 HIJM54-11 67 Clinical Evaluation of Low-dose Cisplatin and 5-Fluorouracil as Adjuvant Chemoradiotherapy for Advanced Squamous Cell Carcinoma
More informationOriginal Article. Keywords: Esophageal cancer; preoperative chemotherapy; regression; prognosis
Original Article The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality
More informationClinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?
Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More information